Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TT0ID4A)

• DTT Name: Leutinizing-hormone-releasing hormone (GNRH1) DTT Info
• Gene Name: GNRH1

Molecule-Related Drug & Molecule List

2 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Goserelin	DMAT8CG	Breast cancer	2C60-2C65	Approved	[1]
Leuprolide	DM5XPIJ	Plasma cell myeloma	2A83.1	Approved	[2]

2 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NAL-GLU	DMD5AEB	Prostate cancer	2C82.0	Phase 2/3	[3]
CG201	DMWY609	Solid tumour/cancer	2A00-2F9Z	Phase 2	[4]

2 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Norelin	DMYCLZR	Prostate cancer	2C82.0	Discontinued in Phase 2	[5]
TAK-810	DMCFOSG	Prostate cancer	2C82.0	Discontinued in Phase 1	[6]

1 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Anti-GnRH Spiegelmer	DM4HKC8	Discovery agent	N.A.	Investigative	[7]

References

• [1] Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):341-9.
• [2] Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer. Pharmacotherapy. 2008 Dec;28(12):1511-22.
• [3] The gonadotropin-releasing hormone antagonist (Nal-Glu) acutely blocks the luteinizing hormone surge but allows for resumption of folliculogenesis in normal women. Am J Obstet Gynecol. 1991 Dec;165(6Pt 1):1811-7.
• [4] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [5] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011623)
• [6] EP patent application no. 2018865, Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an lhrh analogue and/or a bisphosphonate.
• [7] In vivo properties of an anti-GnRH Spiegelmer: an example of an oligonucleotide-based therapeutic substance class. Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8898-902.